Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCL5 | P13501 | 11/20 | 0.56 |
| ▸ | CCR5 | P51681 | 9/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976049 | 1.00 | CCL5 (0.56) | CCL5CCR5KCNH2ALDH1A1MAPT | |
| SCHEMBL2768453 | 0.82 | CCR5 (0.52) | CCL5CCR5KCNH2 | |
| SCHEMBL5772596 | 0.81 | CCL5 (0.48) | CCL5CCR5KCNH2ALDH1A1MAPT | |
| SCHEMBL3600771 | 0.81 | CCL5 (0.48) | CCL5CCR5KCNH2ALDH1A1MAPT | |
| SCHEMBL6011500 | 0.81 | CCL5 (0.48) | CCL5CCR5KCNH2ALDH1A1MAPT | |
| SCHEMBL9539605 | 0.79 | FFAR1 (0.49) | ALDH1A1 | |
| SCHEMBL4977533 | 0.79 | CCL5 (0.52) | CCL5CCR5KCNH2ALDH1A1MAPT | |
| SCHEMBL31265279 | 0.76 | PKM (0.53) | ALDH1A1MAPT | |
| SCHEMBL7194995 | 0.76 | PKM (0.56) | ALDH1A1MAPT | |
| SCHEMBL13547427 | 0.74 | CCR5 (0.61) | CCL5CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| CN-100381423-C | Novel piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2008-04-16 | — | — | CN | disclosed |
| EP-1648871-B1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | ASTRAZENECA AB (SE) | 2007-05-17 | — | — | US | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1654229-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| EP-1648871-A1 | PIPERIDINE OR 8-AZA-BICYCLO 3.2.1 OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| CN-1732153-A | Novel piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2006-02-08 | — | — | CN | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005007629-A1 | PIPERIDINE OR 8-AZA-BICYCLO[3.2.1]OCT-3-YL DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | CCL5 8/4885CCR5 1/4885KCNH2 2940/4885 |
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | CCR5, CCR2, CCR7 | CCL5 14/4885CCR5 1/4885KCNH2 1750/4885 |
| US-20070112022-A1 | Piperidine derivatives as ccr5 receptor modulators | CCR5, CCR2, CCR6 | CCL5 21/4885CCR5 1/4885KCNH2 2301/4885 |
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | CCL5 11/4885CCR5 1/4885KCNH2 2437/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | CCL5 8/4885CCR5 1/4885KCNH2 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.